Led · Seed · Jun 2026

Founded in 2025, BCI-Sonics is developing low-intensity focused ultrasound technology intended to non-invasively stimulate deep brain regions with precision down to 1.5 millimetres. The company combines that focused ultrasound capability with AI-powered closed-loop neural modulation to enable real-time reading and adjustment of brain stimulation. BCI-Sonics targets therapeutic applications for conditions such as Parkinson's disease and chronic pain and also aims at consumer health use cases. It is collaborating with universities and hospitals to validate clinical applications as it advances toward commercialisation. The company reported raising just over CNY 100 million ($14M) in an angel/angel+ round to fund development and validation work.

Participated · Series B · Jan 2026

Neowise (新景智源生物科技) focuses on the discovery and development of TCR-T immunotherapies aimed at solid tumors. The company has built a proprietary high-throughput, high-sensitivity target-antigen/TCR discovery platform (CAST®) that combines AI computation with experimental validation to rapidly identify high-affinity, tumor-specific TCR sequences. Its lead candidate, NW-101C, targets PRAME and is the first domestic therapy against this antigen to reach clinical trials, currently in a Phase I registration study across multiple late-stage solid tumors. A second candidate, NW-301V, targets the KRAS G12V mutation and delivered an objective response rate of 50% and a disease control rate of 100% in an early trial involving 14 evaluable colorectal and pancreatic cancer patients, with no dose-limiting toxicities observed. Over the past two years the company has advanced two programs into the clinic, validating its platform capabilities. Proceeds from the latest financing will fund further clinical development of these core assets and advance multiple preclinical programs, while supporting commercialization and international expansion efforts. The firm has received continued backing from existing investors alongside new institutional support, underscoring confidence in its pipeline and platform.

Led · Series A · Aug 2023

Hunan Quanyu Industrial Equipment Co., Ltd. (Quanyu Industrial) develops and supplies automated robotic grinding equipment for castings. The company focuses on automation R&D and commercialization of casting-grinding robots and related market work. Its product lineup includes heavy-duty grinding robot series, fine-grinding robot units, and high-rigidity robot fine-grinding units. Quanyu provides both equipment and services to users in need of automated casting finishing. The company recently completed a Series A financing of nearly ¥100 million RMB to support its growth. Proceeds are earmarked for capacity expansion, product iteration, and implementation of new business models.

Led · Series A · Sep 2022

Redbud Medicine is a Delaware-headquartered clinical contract research organization (CRO) offering science-based clinical development services. It provides full-service development from bench to bedside, aiming to reduce traditional clinical study timelines, improve overall quality, and contain costs. The company’s global team has extensive experience across a broad range of therapeutic areas and global clinical development. Services include protocol design, case report form (CRF) creation, ongoing medical review through the final clinical study report (CSR), plus digital solutions and training for sponsors new to drug development. Redbud plans to use the Series A proceeds to streamline execution of clinical trials across those stages. The article reports the company raised $10M in Series A funding.

Participated · Series A · Mar 2020

Amunix Pharmaceuticals is a South San Francisco-based biopharmaceutical company focused on developing masked, protease-activated immune-oncology therapeutics. It leverages proprietary XPAT® and XPAC™ platforms to advance drugs that are preferentially activated in the tumor microenvironment and designed to overcome toxicity challenges of other T cell and cytokine therapies. Its proprietary masking technology has been clinically validated to extend drug half-life with limited immunogenicity. The company’s pipeline includes AMX-818, an XPAT® T cell engager targeting HER2-expressing solid tumors currently in IND-enabling studies, and an IL12-XPAC™ masked cytokine program in discovery. Led by CEO Angie You, Ph.D., Amunix raised $117M in a Series B financing to advance AMX-818 into the clinic and to support its earlier-stage XPAT and XPAC programs. The funding will be used to support clinical translation and continued development of its masked, protease-activated product candidates. Amunix Pharmaceuticals develops prodrugs to enable potent immune-activating biotherapeutics for patients with solid tumor cancers. Its pipeline centers on XPAT T cell engagers and XPAC cytokines that are selectively activated in the tumor microenvironment to mitigate toxicity and immunogenicity. Both platforms leverage the company’s clinically validated XTEN and Pro‑XTEN technologies to generate masked, protease‑releasable prodrugs with low immunogenicity. With the $73 million Series A and a prior $40 million upfront from a Roche licensing agreement, Amunix plans to advance lead candidate AMX‑818 (an XPAT targeting HER2+ solid tumors) into the clinic and progress earlier discovery-stage XPAT programs. The company also intends to initiate XPAC discovery work and relocate to South San Francisco to access talent. Founded in 2006, Amunix previously operated as a technology licensing company and has refocused on internal development since appointing Dr. Angie You as CEO in January 2019. The executive team includes industry veterans such as Mika Derynck (CMO), Maninder Hora (CTOO), Bryan Irving (CSO), and Darcy Mootz (CBO).